145 related articles for article (PubMed ID: 11105814)
1. Does thyroid stunning exist? A model with benign thyroid disease.
Sabri O; Zimny M; Schreckenberger M; Meyer-Oelmann A; Reinartz P; Buell U
Eur J Nucl Med; 2000 Nov; 27(11):1591-7. PubMed ID: 11105814
[TBL] [Abstract][Full Text] [Related]
2. Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I.
Hilditch TE; Dempsey MF; Bolster AA; McMenemin RM; Reed NS
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):783-8. PubMed ID: 12029552
[TBL] [Abstract][Full Text] [Related]
3. The role of 123I-diagnostic imaging in the follow-up of patients with differentiated thyroid carcinoma as compared to 131I-scanning: avoidance of negative therapeutic uptake due to stunning.
Siddiqi A; Foley RR; Britton KE; Sibtain A; Plowman PN; Grossman AB; Monson JP; Besser GM
Clin Endocrinol (Oxf); 2001 Oct; 55(4):515-21. PubMed ID: 11678835
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET.
Eschmann SM; Reischl G; Bilger K; Kupferschläger J; Thelen MH; Dohmen BM; Besenfelder H; Bares R
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):760-7. PubMed ID: 12029549
[TBL] [Abstract][Full Text] [Related]
5. Success rate of radioiodine therapy in Graves' disease: the influence of thyrostatic medication.
Sabri O; Zimny M; Schulz G; Schreckenberger M; Reinartz P; Willmes K; Buell U
J Clin Endocrinol Metab; 1999 Apr; 84(4):1229-33. PubMed ID: 10199759
[TBL] [Abstract][Full Text] [Related]
6. A case of stunning of lung and bone metastases of papillary thyroid cancer after a therapeutic dose (3.7 GBq) of 131I and review of the literature: implications for sequential treatments.
Leger AF; Pellan M; Dagousset F; Chevalier A; Keller I; Clerc J
Br J Radiol; 2005 May; 78(929):428-32. PubMed ID: 15845937
[TBL] [Abstract][Full Text] [Related]
7. 131I therapeutic efficacy is not influenced by stunning after diagnostic whole-body scanning.
Dam HQ; Kim SM; Lin HC; Intenzo CM
Radiology; 2004 Aug; 232(2):527-33. PubMed ID: 15286323
[TBL] [Abstract][Full Text] [Related]
8. Influence of 131I diagnostic dose on subsequent ablation in patients with differentiated thyroid carcinoma: discrepancy between the presence of visually apparent stunning and the impairment of successful ablation.
Hu YH; Wang PW; Wang ST; Lee CH; Chen HY; Chou FF; Huang YE; Huang HH
Nucl Med Commun; 2004 Aug; 25(8):793-7. PubMed ID: 15266173
[TBL] [Abstract][Full Text] [Related]
9. The nonimpact of thyroid stunning: remnant ablation rates in 131I-scanned and nonscanned individuals.
Morris LF; Waxman AD; Braunstein GD
J Clin Endocrinol Metab; 2001 Aug; 86(8):3507-11. PubMed ID: 11502771
[TBL] [Abstract][Full Text] [Related]
10. Absence of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I.
Cholewinski SP; Yoo KS; Klieger PS; O'Mara RE
J Nucl Med; 2000 Jul; 41(7):1198-202. PubMed ID: 10914909
[TBL] [Abstract][Full Text] [Related]
11. Radiation dose to patients and relatives incident to 131I therapy.
Zanzonico PB
Thyroid; 1997 Apr; 7(2):199-204. PubMed ID: 9133684
[TBL] [Abstract][Full Text] [Related]
12. Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer.
de Keizer B; Hoekstra A; Konijnenberg MW; de Vos F; Lambert B; van Rijk PP; Lips CJ; de Klerk JM
J Nucl Med; 2004 Sep; 45(9):1549-54. PubMed ID: 15347723
[TBL] [Abstract][Full Text] [Related]
13. [Stunning in radioiodine therapy of benign thyroid disease. Quantification and therapeutic relevance].
Krohn T; Meyer PT; Ocklenburg C; Knollmann D; Nowak B; Schaefer WM
Nuklearmedizin; 2008; 47(6):248-54. PubMed ID: 19057798
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic 123I and 131I activities and radioiodine therapy. Effects on urinary iodine excretion in patients with differentiated thyroid carcinoma.
Meller B; von Hof K; Genina E; Deisting W; Meller J; Richter E; Baehre M
Nuklearmedizin; 2005; 44(6):243-8. PubMed ID: 16400384
[TBL] [Abstract][Full Text] [Related]
15. Determinants of longterm outcome of radioiodine therapy of sporadic non-toxic goitre.
Le Moli R; Wesche MF; Tiel-Van Buul MM; Wiersinga WM
Clin Endocrinol (Oxf); 1999 Jun; 50(6):783-9. PubMed ID: 10468951
[TBL] [Abstract][Full Text] [Related]
16. A quantitative study about thyroid stunning after diagnostic whole-body scanning with 74 MBq 131I in patients with differentiated thyroid carcinoma.
Yin Y; Mao Q; Chen S; Li N; Li X; Li Y
Q J Nucl Med Mol Imaging; 2015 Dec; 59(4):455-61. PubMed ID: 26416037
[TBL] [Abstract][Full Text] [Related]
17. Thyroid stunning in vivo and in vitro.
Medvedec M
Nucl Med Commun; 2005 Aug; 26(8):731-5. PubMed ID: 16000993
[TBL] [Abstract][Full Text] [Related]
18. Thyroid stunning in radioiodine-131 therapy of benign thyroid diseases.
Happel C; Kranert WT; Ackermann H; Binse I; Bockisch B; Gröner D; Herrmann K; Grünwald F
Endocrine; 2019 Mar; 63(3):537-544. PubMed ID: 30599051
[TBL] [Abstract][Full Text] [Related]
19. A predictive mathematical model for the calculation of the final mass of Graves' disease thyroids treated with 131I.
Traino AC; Di Martino F; Grosso M; Monzani F; Dardano A; Caraccio N; Mariani G; Lazzeri M
Phys Med Biol; 2005 May; 50(9):2181-91. PubMed ID: 15843745
[TBL] [Abstract][Full Text] [Related]
20. Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of 131I?
Kobe C; Eschner W; Wild M; Rahlff I; Sudbrock F; Schmidt M; Dietlein M; Schicha H
Nucl Med Commun; 2010 Mar; 31(3):201-5. PubMed ID: 19907353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]